COPENHAGEN (Reuters) - Novo Nordisk might be able to complete an acquisition within its struggling biopharma business this year, its chief executive told Reuters on Monday.
"It is not always easy to predict when a transaction goes through, but we are in enough ongoing discussions that it might be possible this year if all goes well," CEO Lars Fruergaard Jorgensen said, declining to provide more detail on the potential deal.
Novo announced on Monday it had hired an AstraZeneca executive to head its biopharma business.
(Reporting by Stine Jacobsen; editing by Jason Neely)
Disclaimer: No Business Standard Journalist was involved in creation of this content
